Premium
Genetic variation in the toll‐like receptor 4 and prostate cancer incidence and mortality
Author(s) -
Shui Irene M.,
Stark Jennifer R.,
Penney Kathryn L.,
Schumacher Fredrick R.,
Epstein Mara M.,
Pitt Michael J.,
Stampfer Meir J.,
Tamimi Rulla M.,
Lindstrom Sara,
Sesso Howard D.,
Fall Katja,
Ma Jing,
Kraft Peter,
Giovannucci Edward,
Mucci Lorelei A.
Publication year - 2011
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.21423
Subject(s) - prostate cancer , medicine , single nucleotide polymorphism , oncology , prostate , cancer , incidence (geometry) , prospective cohort study , genotype , biology , genetics , gene , physics , optics
BACKGROUND Common genetic variants in the Toll‐like receptor 4 (TLR4), which is involved in inflammation and immune response pathways, may be important for prostate cancer. METHODS In a large nested case–control study of prostate cancer in the Physicians' Health Study (1982–2004), 10 single nucleotide polymorphisms (SNPs) were selected and genotyped to capture common variation within the TLR4 gene as well as 5 kb up and downstream. Unconditional logistic regression was used to assess associations of these SNPs with total prostate cancer incidence, and with prostate cancers defined as advanced stage/lethal (T3/T4, M1/N1(T1–T4), lethal) or high Gleason grade (7 (4 + 3) or greater). Cox‐proportional hazards regression was used to assess progression to metastases and death among prostate cancer cases. RESULTS The study included 1,267 controls and 1,286 incident prostate cancer cases, including 248 advanced stage/lethal and 306 high grade cases. During a median follow‐up of 10.6 years, 183 men died of prostate cancer or developed distant metastases. No statistically significant associations between the TLR4 SNPs were found for total prostate cancer incidence, including SNPs for which an association was reported in other published studies. Additionally, there were no significant associations with TLR4 SNPS and the incidence of advanced stage/lethal, or high grade cancers; nor was there evidence among prostate cancer cases for associations of TLR4 SNPs with progression to prostate cancer specific mortality or bony metastases. CONCLUSIONS Results from this prospective nested case–control study suggest that genetic variation across TLR4 alone is not strongly associated with prostate cancer risk or mortality. Prostate 72:209–216, 2012. © 2011 Wiley Periodicals, Inc.